Company: EDSA
Filing Date: 2025-12-12
Form Type: 10-K
Source: 0001171843-25-007914
Chunk: 1329

Company: Edesa Biotech, Inc.
Filing Date: 2025-12-12
Form: 10-K
Item: Item 9C
Chunk 1329
---
The required upfront license payment of $2.5 million was paid by issuance of Series A-1 Convertible Preferred Shares, which have been fully converted to common shares. The value of the license includes acquisition legal costs. See Note 6 for license commitments.

F-12

EDESA BIOTECH, INC.

Notes to Consolidated Financial Statements

For the Years Ended September 30, 2025 and 2024

Intangible assets, net consisted of the following:

			September 30, 2025 

			September 30, 2024 

			The Constructs

			$
			2,529,483

			$
			2,529,483

			Less: accumulated amortization

			(551,807
			)

			(450,635
			)

			Total intangible assets, net

			$
			1,977,676

			$
			2,078,848

Amortization expense amounted to $101,172 for each of the years ended September 30, 2025, and 2024, respectively.

Total estimated future amortization of intangible assets for each fiscal year is as follows:

			Year Ending

			September 30, 2026

			101,172

			September 30, 2027

			101,172

			September 30, 2028

			101,172

			September 30, 2029

			101,172

			September 30, 2030

			101,172

			Thereafter

			1,471,816

			$
			1,977,676

5. Right-of-Use Asset and Liabilities

Related party ROU asset and liability 

The Company leases a facility used for executive offices from a related company. The original lease expired in December 2022 and the Company executed a two-year term extension through December 31, 2024.

The components of lease cost were as follows:

			Fiscal Year End 

			September 30, 2025

			September 30, 2024

			Right-of-use lease cost, included in general and administrative on the Statements of Operations

			$
			17,893

			$
			78,073

Lease terms and discount rates were as follows:

			September 30, 2025